OpenEvidence Inc., the developer of an artificial intelligence search engine for doctors, today announced that it has closed a $200 million investment.

The Series C round was led by Alphabet Inc.’s GV fund. Sequoia, Kleiner Perkins, Blackstone, Thrive Capital, Coatue, Bond and Craft participated as well. OpenEvidence is now worth $6.5 million, up from $3.5 billion following another GV-led funding round in July.

OpenEvidence’s namesake AI search engine enables doctors to browse medical literature through a ChatGPT-like interface. It can generate multi-paragraph natural language answers to user questions. In addition, OpenEvidence displays citations that can be used to find the research papers from which it retrieved information. The platform aggregates papers from the JAMA Network, a consortium of scientific publications published by the American Medical Association, the New England Journal of Medicine and other sources.

Medical professionals can use the service to support care delivery. A doctor could, for example, ask OpenEvidence to list recommended lab tests and treatment options. The service also lends itself to researching broader topics. It can summarize new research papers and provide explainers about emerging medical technologies.

In medical schools, lecturers can use OpenEvidence to draft exam questions. The service supports multiple question formats and surfaces research papers with relevant information. 

In August, OpenEvidence became the first AI platform to achieve a perfect score on the U.S. Medical Licensing Examination. The second highest score was earned by GPT-5, which answered 97% of the questions correctly. OpenEvidence disclosed on the milestone that more than 75,000 U.S. clinicians sign up for its platform per month. 

The company’s software is already used by about 40% of the physicians in the U.S. They run 16.5 million searches per month, up from 10 million in June. OpenEvidence provides its platform for free to medical professionals and makes money through advertising. According to Forbes, OpenEvidence expects its annualized recurring revenue to grow from $50 million in July to $100 million next year. 

In August, the company expanded its focus beyond AI search by launching a new tool called Visits. It automatically generates medical notes from patient conversations. Doctors can also use Visits to search medical documentation for specific details and enrich it with external data.

OpenEvidence’s rapid user growth could prompt other chatbot developers to increase their focus on the healthcare sector. Against the backdrop of the company’s funding announcement today, Anthropic PBC launched a feature that enables Claude to analyze RNA sequencing data. A second enhancement introduced in conjunction will make the chatbot better at running queries on biomedical literature. 

Photo: Pixabay